JP2004536605A - インターロイキン１β抗体 - Google Patents

インターロイキン１β抗体 Download PDF

Info

Publication number
JP2004536605A
JP2004536605A JP2003515633A JP2003515633A JP2004536605A JP 2004536605 A JP2004536605 A JP 2004536605A JP 2003515633 A JP2003515633 A JP 2003515633A JP 2003515633 A JP2003515633 A JP 2003515633A JP 2004536605 A JP2004536605 A JP 2004536605A
Authority
JP
Japan
Prior art keywords
antibody
seq
human
sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003515633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536605A5 (https=
Inventor
スチュアート・ウィリス・ブライト
ジャ・オードリー・ユンファ
スチュアート・アレン・クストス
ジョゼフ・ビンセント・マネッタ
ナオヤ ツルシタ
マクシミリアノ・ホタ・バスケス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2004536605A publication Critical patent/JP2004536605A/ja
Publication of JP2004536605A5 publication Critical patent/JP2004536605A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003515633A 2001-07-26 2002-07-18 インターロイキン１β抗体 Pending JP2004536605A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30797301P 2001-07-26 2001-07-26
US31227801P 2001-08-14 2001-08-14
PCT/US2002/021281 WO2003010282A2 (en) 2001-07-26 2002-07-18 Interleukin-1 beta antibodies

Publications (2)

Publication Number Publication Date
JP2004536605A true JP2004536605A (ja) 2004-12-09
JP2004536605A5 JP2004536605A5 (https=) 2006-01-05

Family

ID=26976031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003515633A Pending JP2004536605A (ja) 2001-07-26 2002-07-18 インターロイキン１β抗体

Country Status (8)

Country Link
US (1) US20050075488A1 (https=)
EP (1) EP1423432A4 (https=)
JP (1) JP2004536605A (https=)
AR (1) AR036189A1 (https=)
AU (1) AU2002355249A1 (https=)
PE (1) PE20030282A1 (https=)
SV (1) SV2003001183A (https=)
WO (1) WO2003010282A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543340A (ja) * 2005-06-21 2008-12-04 ゾーマ テクノロジー リミテッド ＩＬ−１β結合抗体およびその断片
JP2009501703A (ja) * 2005-06-24 2009-01-22 デューク・ユニヴァーシティ 熱応答性バイオポリマーに基づく直接的ドラッグデリバリーシステム
JP2011507891A (ja) * 2007-12-20 2011-03-10 ゾーマ テクノロジー リミテッド 痛風の治療のための方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481010A2 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
EP1590369B1 (en) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
TR201802449T4 (tr) * 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2673592C (en) 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
CA2839162A1 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Methods for the treatment of il-1-.beta. related diseases
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
EP2341936A4 (en) 2008-09-05 2012-07-25 Xoma Technology Ltd METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
US20110307788A1 (en) * 2010-06-15 2011-12-15 Microsoft Corporation Role-based presentation views
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
US10436795B2 (en) * 2016-09-16 2019-10-08 Institute For Cancer Research Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
JP2003523724A (ja) 1999-03-12 2003-08-12 エグゼリクシス プラント サイエンシーズ， インコーポレイテッド 形質関連遺伝子の同定方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543340A (ja) * 2005-06-21 2008-12-04 ゾーマ テクノロジー リミテッド ＩＬ−１β結合抗体およびその断片
JP4931919B2 (ja) * 2005-06-21 2012-05-16 ゾーマ テクノロジー リミテッド ＩＬ−１β結合抗体およびその断片
JP2009501703A (ja) * 2005-06-24 2009-01-22 デューク・ユニヴァーシティ 熱応答性バイオポリマーに基づく直接的ドラッグデリバリーシステム
JP2011507891A (ja) * 2007-12-20 2011-03-10 ゾーマ テクノロジー リミテッド 痛風の治療のための方法

Also Published As

Publication number Publication date
SV2003001183A (es) 2003-07-29
WO2003010282A3 (en) 2004-02-12
EP1423432A4 (en) 2006-01-11
AU2002355249A1 (en) 2003-02-17
US20050075488A1 (en) 2005-04-07
EP1423432A2 (en) 2004-06-02
PE20030282A1 (es) 2003-03-25
WO2003010282A2 (en) 2003-02-06
AR036189A1 (es) 2004-08-18

Similar Documents

Publication Publication Date Title
CN103154029B (zh) 抗人tweak的抗体及其用途
TWI393570B (zh) 抗人類ｉｌ１７之抗體及其用途
JP5420399B2 (ja) 改変型ヒト化抗インターロイキン−１８抗体
JP3978338B2 (ja) ヒトＩＬ−１βに対する抗体
EP4289861A1 (en) Antibodies against human tslp and use thereof
CA2959551C (en) Anti-tnf-/anti-il-23 bispecific antibodies
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP2004536605A (ja) インターロイキン１β抗体
US20160251430A1 (en) Anti-baff-anti-il-17 bispecific antibodies
KR20120075457A (ko) 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도
JP2005518802A (ja) 抗インターロイキン−１ベータ類縁体
CN113056480B (zh) 人源化抗N截短淀粉样β单克隆抗体
JP2025041747A (ja) ヒト化抗ｉｌ１７ｂｒ抗体
CN117015553A (zh) 包含白细胞介素-18结合蛋白和抗血清白蛋白的抗原结合片段的重组融合蛋白及其组合物和用途
KR20250050855A (ko) Igf1r 항체
JP2026503565A (ja) 全身性エリテマトーデスの治療方法
WO2023241389A1 (zh) 针对tfpi的单克隆抗体及其用途
WO2022262828A1 (zh) 抗il-36r抗体及其用途
TW202136308A (zh) 抗ｃｓｆ１ｒ分子及其用途
HK1186195B (en) Antibodies against human tweak and uses thereof
HK1163131A (en) Antibodies against human tweak and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080731

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080901

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080908

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090113